Table 3.
Trials evaluating nicotinamide and carbogen as radiosensitizers, sorted by publication year
| Author | Year | Agent | Dose | n | Radiation regimen | Results |
|---|---|---|---|---|---|---|
| Van der Maazen et al. [24] | 1995 |
Carbogen Nicotinamide |
5 min pre + during RT 6 g |
16 (14) | 50 Gy in 25 fractions |
Median OS: 233 days High hepatic and neurotoxicity |
| Pickles et al. [25] | 1996 |
Carbogen Nicotinamide |
5–15 min pre RT 6 g, later 80 mg/kg |
19 |
54 Gy in 30 fractions Later 50.1 in 30 fractions |
Median OS: 8.5 months High hepatic toxicity |
| Fatigante et al. [26] | 1997 |
Carbogen Nicotinamide |
10 min pre + during RT 4 g + 2 g daily |
36 | 60 Gy in 40 fractions bid |
Median OS: 10 months High gastric and hepatic toxicity |
| Lambin et al. [27] | 1997 |
Carbogen Nicotinamide |
5 min pre + during RT 6 g |
12 | 60 Gy in 30 fractions tid |
Median OS: 7.2 months High hepatic and neurotoxicity |
| Miralbell et al. [28] | 1999 |
Carbogen (C) Nicotinamide (N) |
5 min pre + during RT 85 mg/kg |
115 | 60 Gy in 40 fractions bid |
Median OS: 11.1 months (RT + C + N) vs 10.1 months (RT + C) vs 9.7 months (RT + N) |
| Simon et al. [23] | 2003 |
Carbogen Nicotinamide + ACNU |
5 min pre + during RT 85 mg/kg 100 mg/m2, 3 cycles |
33 | 59.4 Gy in 33 fractions |
Median OS: 36.7 weeks High gastric toxicity |
n = number of patients included (number of patients with glioblastoma in parentheses if multiple entities were included)